B+
Bull case
20%
Probability
Target price
$6.10
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
EBS
Emergent BioSolutionsDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 demonstrated strong revenue and adjusted EBITDA performance, while biodefense contract activity and strategic manufacturing partnerships could support diversification if execution persists [#SEC-8K-2026-08-05][#SEC-8K-2026-04-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.5.
What can break
Coverage, verified analyst revisions, social data, options data, and short-interest data are unavailable.
Momentum
3
Value
73
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $6.10 · Bear $3.20Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum3 · Δ7d +0.7
Value73 · Δ7d -0.0
Sentiment40 · Δ7d +7.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +7.5.
Contradictions & invalidation
- • Coverage, verified analyst revisions, social data, options data, and short-interest data are unavailable.
- • Future U.S. distribution rights for the Japanese Encephalitis vaccine depend on FDA approval [#SEC-8K-2026-04-30].
- • The large impairment, naloxone pressure, restructuring charges, and low visibility into repeatable demand leave substantial downside if government-contract timing or turnaround execution weakens.
Catalyst clock
2026-08-05
Strong Q2 biodefense execution, offset by impairment
Lead driver: Sentiment · See AI snapshot
Momentum
3
9% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+0.7
Value
73
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
40
62% active weight
Current posture
7d trendImproving
Δ7d
+7.5
Δ21d
-26.0
Why this grade
Composite grade D. Momentum 2.7 / Value 72.8 / Sentiment 39.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$230.73M
Beta
2.35
Shares Out
51.27M
P/E (TTM)
9.9
P/S (TTM)
0.86
P/FCF (TTM)
482.06
Rev YoY
+66.3%
EPS YoY
+1477.3%
Gross Margin
+47.2%
Op Margin
+17.8%
Net Debt
$374.6M
Current Ratio
5.42
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data